Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06643741
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-14
Brief Title:
Non-Invasive Preeclampsia Screening and Biobank
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Collection of Pregnancy Outcome Data and Whole Blood Samples From Women Undergoing Non-Invasive Screening for Early Preterm and Term Preeclampsia
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Women pregnant between 11-14 weeks gestation will be enrolled with blood samples collected to evaluate for preeclampsia
Detailed Description:
To collect relevant pregnancy outcome data medical history and blood samples from pregnant women carrying a singleton fetus undergoing non-invasive screening for early preterm and term pre-eclampsia PE starting at 11 weeks 0 days to 14 weeks 0 days 11 - 14 gestation in support of validating the Labcorp Preeclampsia ScreenTM assay Data will be used to examine assay performance and develop new testing methods
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None